Daiwa Securities Group Inc. Buys 8,890 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Daiwa Securities Group Inc. raised its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 12.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 82,361 shares of the company's stock after acquiring an additional 8,890 shares during the quarter. Daiwa Securities Group Inc.'s holdings in GE HealthCare Technologies were worth $7,730,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Summit Trail Advisors LLC increased its position in GE HealthCare Technologies by 15.0% in the 3rd quarter. Summit Trail Advisors LLC now owns 4,898 shares of the company's stock valued at $460,000 after acquiring an additional 638 shares in the last quarter. Centaurus Financial Inc. increased its position in GE HealthCare Technologies by 20.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,980 shares of the company's stock valued at $186,000 after acquiring an additional 330 shares in the last quarter. Larson Financial Group LLC increased its position in GE HealthCare Technologies by 223.3% in the 3rd quarter. Larson Financial Group LLC now owns 3,142 shares of the company's stock valued at $295,000 after acquiring an additional 2,170 shares in the last quarter. Swedbank AB increased its position in GE HealthCare Technologies by 6.6% in the 3rd quarter. Swedbank AB now owns 72,013 shares of the company's stock valued at $6,758,000 after acquiring an additional 4,490 shares in the last quarter. Finally, CMG Global Holdings LLC boosted its stake in shares of GE HealthCare Technologies by 2.3% in the 3rd quarter. CMG Global Holdings LLC now owns 11,824 shares of the company's stock valued at $1,110,000 after purchasing an additional 271 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Analyst Upgrades and Downgrades

GEHC has been the topic of several recent research reports. BTIG Research raised shares of GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a research note on Wednesday, September 18th. UBS Group lowered shares of GE HealthCare Technologies from a "neutral" rating to a "sell" rating and reduced their target price for the company from $84.00 to $74.00 in a research note on Thursday, September 26th. JPMorgan Chase & Co. initiated coverage on shares of GE HealthCare Technologies in a research note on Monday, September 9th. They issued a "neutral" rating and a $90.00 target price on the stock. Redburn Atlantic raised shares of GE HealthCare Technologies to a "strong-buy" rating in a research note on Thursday, August 1st. Finally, Stifel Nicolaus raised their target price on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a "buy" rating in a research note on Monday, September 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $94.36.

Insider Activity

In related news, CEO Roland Rott sold 3,577 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the transaction, the chief executive officer now directly owns 24,298 shares in the company, valued at approximately $2,101,291.04. The trade was a 12.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.27% of the stock is owned by corporate insiders.

GE HealthCare Technologies Stock Down 0.2 %

GEHC stock traded down $0.15 during mid-day trading on Tuesday, hitting $82.51. 2,040,472 shares of the company were exchanged, compared to its average volume of 3,084,686. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.98 and a current ratio of 1.23. The firm has a market cap of $37.70 billion, a P/E ratio of 22.67, a P/E/G ratio of 2.95 and a beta of 1.24. The firm's 50 day simple moving average is $88.27 and its 200 day simple moving average is $83.62. GE HealthCare Technologies Inc. has a 1-year low of $66.39 and a 1-year high of $94.55.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company had revenue of $4.86 billion for the quarter, compared to the consensus estimate of $4.87 billion. During the same period last year, the company earned $0.99 earnings per share. The firm's revenue was up .9% compared to the same quarter last year. On average, sell-side analysts predict that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be issued a $0.035 dividend. The ex-dividend date is Tuesday, January 14th. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.03. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.17%. GE HealthCare Technologies's dividend payout ratio (DPR) is 3.30%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.